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1 |  INTRODUCTION
A 67-year-old man presented with left-sided weakness and 
reduced left-hand dexterity four months after autologous 
stem cell transplant (ASCT) for multiple myeloma (MM). 
Clinical neurological examination was felt to be normal. 
Three months later, he reported progressive worsening of this 
weakness; neurological examination showed mild left-sided 
facial asymmetry.
He was diagnosed with IgG lambda MM in March 2016 
during follow-up of lytic lesions on a chest radiograph per-
formed because of recurrent chest infections. His past medical 
history included chronic obstructive pulmonary disease and 
controlled hypertension. He was human immunodeficiency 
virus (HIV) negative. He underwent induction treatment with 
four cycles of bortezomib, thalidomide, and dexamethasone 
starting in April 2016, complicated by neutropenic sepsis 
requiring intensive care for high-flow oxygen and granulo-
cyte-colony stimulating factor. He also developed thrombosis 
of his peripherally inserted central catheter, treated with low 
molecular weight heparin. ASCT with melphalan conditioning 
(200 mg/m2) was carried out in January 2017. On day 7 fol-
lowing ASCT, he developed neutropenic sepsis from urinary 
Escherichia coli. He took routine post-transplant Pneumocystis 
jirovecii prophylaxis trimethoprim/sulfamethoxazole, which 
was switched to pentamidine in April 2017 because of slow 
platelet count recovery. This stopped in July 2017. In March 
2017, he had an episode of herpes zoster affecting the left trunk.
General weakness is common in the months following 
transplant as the patient recovers from the intensive treatment, 
complications and hospital admission. The focal progressive 
symptoms and new findings on neurological examination are 
much more concerning. There is a wide differential diagno-
sis, including cerebrovascular disease, demyelinating illness 
and space occupying lesions.
Computerized tomography (CT) scan of the head was 
performed which showed multiple areas of low attenuation 
(Figure 1).
The radiological findings were thought to represent 
multiple areas of infarction, likely embolic in nature. The 
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Abstract
PML should be considered in patients with neurological symptoms following MM 
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progressing. Prompt referral and early involvement of the multidisciplinary team are 
crucial.
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progressive nature of the weakness could represent multiple 
infarcts over time. The patient had several risk factors for 
stroke: smoking history, hypertension, malignancy, and treat-
ment with chemotherapy. 1 The complication of peripherally 
inserted central catheter thrombosis could also point toward a 
predisposition for thrombosis.
Magnetic Resonance Imaging (MRI) of the brain showed 
numerous hyper-intense T2 lesions within the subcortical 
white matter of both cerebral hemispheres (Figure 2). The 
MRI was repeated one month later and showed interval pro-
gression in lesion size (Figure 3).
The MRI head showed multiple areas T2 high signal 
in the white matter, in keeping with demyelination. This 
is a feature of several neurological conditions, including 
hypoxic/ ischemic insults, inflammation (multiple sclero-
sis, acute disseminated encephalomyelitis, vasculitis, and 
sarcoidosis), metabolic/toxic causes (carbon monoxide 
poisoning, vitamin B12 deficiency, central pontine myeli-
nolysis, inherited leukodystrophies), and infections (HIV, 
syphilis, lyme disease, and progressive multifocal leukoen-
cephalopathy (PML)).
His clinical symptoms continued to progress, and by 
September 2017, he was unable to walk 2 m unaided. He de-
veloped emotional lability and motion sickness. There was no 
alteration in sensation, sphincter or bulbar symptoms, and he 
had no weight loss, night sweats or fevers.
F I G U R E  1  Computerized tomography (CT) scan of the head 
was performed which showed multiple areas of low attenuation, as 
shown by the white arrow
F I G U R E  2  Magnetic resonance imaging of the brain showed 
numerous hyper-intense T2 lesions within the subcortical white matter 
of both cerebral hemispheres
F I G U R E  3  Magnetic resonance imaging (MRI) repeated one 
month after the MRI shown in Figure 1 shows interval progression in 
lesion size
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Examination showed normal tone bilaterally. There was 
mild left-sided weakness of the face and left-sided hemi-
paresis, worse than previous. Reflexes in the legs were 
brisk with some spreading, and the left plantar response 
was up-going. Gait was narrow-based, stiff and hemiple-
gic. There were no cerebellar signs. Sensation was intact. 
Assessment of cognitive function with Addenbrooke's 
Cognitive Examination III-revised (ACE III-R) showed 
mild cognitive impairment with a score of 84/100 (atten-
tion 17/18, memory 21/26, fluency 7/14, language 26/26, 
and visuospatial 13/16).
Interpretation of ACE III-R scores is difficult, and re-
peated tests at different points in time are the best way to 
show cognitive decline. A score of less than 88 gives a signif-
icant likelihood of dementia 2; thus, in our patient, a score of 
84 demonstrates probable cognitive impairment.
Further investigations were performed to determine the 
cause of the demyelination. A CT chest, abdomen, and pel-
vis showed no evidence of systemic disease, such as solid 
malignancy. Serum serology was negative for HIV, syphi-
lis, and lyme disease. Connective tissue autoimmune screen 
was negative, with no evidence of systemic vasculitis, and 
vitamin B12 levels were normal. A lumbar puncture showed 
normal cell count (red blood cell 0 × 1012/L, white blood 
cell 2  ×  109/L), protein (0.37  mg/dL), glucose (3.4  mg/
dL), and no oligoclonal bands in serum or cerebrospinal 
fluid (CSF). Viral polymerase chain reaction was negative 
for enteroviruses, herpes simplex virus 1 & 2, parechovi-
rus, and varicella zoster virus, and there were no abnor-
mal cells on microscopy. John Cunningham polyomavirus 
virus (JCPyV), the causative agent of PML, was positive 
in serum (1.55 index value); CSF testing for JCPyV was 
strongly positive at a value of 830 000 copies/ml. TA
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T A B L E  2  Measures of immune functioning at the time of 
diagnosis of PML
Immune measure Result
Lymphocytes (1.5-4 cells 109/L) 0.41
B cells (10%-16%) 43
T-cells (67%-76%) 40
CD4 absolute (500-1500 cells u/L) 72
CD4% (29%-61%) 18
CD8 absolute (250-750 cells u/L) 90
CD8% (14%-44%) 22
CD4/CD8 ratio (0.9-3.5) 0.8
Natural killer cells (10%-15%) 16
C3 (0.81-1.57 g/L) 1.44
C4 (0.13-1.39 g/L) 0.34
IgA (6-15 g/L) 0.58
IgG (0.8-4.5 g/L) 6.82
IgM (0.35-2.9 g/L) 0.29
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Seropositivity for JCPyV in this patient was not unex-
pected as between 38% and 82% of the normal population 
have positive serology, but the virus should not be present 
in the CSF.3,4 The positive CSF for JCPyV with compat-
ible clinical and radiological findings fulfill the diagnos-
tic criteria for PML,5 and there was no diagnostic need to 
perform a brain biopsy. This diagnosis was unexpected as 
the patient did not appear to be significantly immunocom-
promised following ASCT and PML is rare in this patient 
group.
Key blood results before and after ASCT are shown in 
Table 1, and further measures of immune functioning were 
taken after the diagnosis of PML to evaluate scope for opti-
mization of immune function (Table 2).
ASCT improves the duration of remission and overall sur-
vival in patients with MM although most patients develop 
relapse of MM after a period of remission. 6-8 The recov-
ery of different immune cells occurs at different time points 
post-transplant. The reconstitution of innate immunity occurs 
rapidly, within 20-30 days, while reconstitution of adaptive 
immunity can take 1 year. 9 Early recovery of absolute lym-
phocyte count (ALC) can be used as a prognostic indicator of 
overall survival and progression free survival. 10 The patient 
followed the usual pace of immune reconstitution, with neu-
trophil recovery at day + 12; implying good immune func-
tioning. Reactivation of varicella zoster virus is common 
after ASCT 11 and does not suggest unusual immunodefi-
ciency for this patient group. The CD4 count is low; in cases 
of HIV-associated PML, there appears to be an association 
between CD4 count and PML. 5
Treatment for JCPyV was commenced with mirtazapine 
30mg once daily and intensive physiotherapy.
Treatment for PML can be tackled in two ways: restoring 
the immune function and attacking the virus. Restoring the 
immune functioning in the patient was problematic as he did 
not appear to have reversible immune suppression beyond 
normal recovery post-ASCT. No methods to restore immune 
function were thought feasible except for the possibility of 
performing a second ASCT using remaining stem cells 
cryopreserved prior to the first ASCT. Several experimen-
tal antiviral therapies were considered, including mirtazap-
ine, which is thought to block virus entry into glial cells via 
5HT2a serotonin receptors. 12 Recently, three groups have re-
ported favorably on the use of immune-checkpoint inhibitors 
to treat PML; immunotherapy appears promising but requires 
further study. 13-15
During admission, his condition continued to worsen. 
He developed hospital acquired pneumonia (HAP) and 
deteriorated rapidly, dying 5  days later. His death was 
18 months after diagnosis of MM, 10 months after ASCT, 
14 days after diagnosis of PML and 10 days after mirtazap-
ine had started. His death was before the second ASCT 
could be attempted.
It was very difficult to give a prognosis to the patient due 
to lack of comparable cases. His rapid deterioration from 
HAP was unexpected. This could reflect a weaker immune 
function than suggested by his blood test results. It was un-
likely that a second stem cell infusion (without conditioning 
chemotherapy) would have promoted immune reconstitution, 
but equally seemed unlikely to cause harm.
2 |  DISCUSSION
PML is a rare demyelinating disorder of the central nerv-
ous system caused by reactivation of JCPyV virus, a neuro-
tropic polyomavirus.16 The clinical presentation depends on 
the extent of demyelination and brain structures involved. 
Symptoms include muscle weakness, sensory deficit, hemi-
anopia, cognitive dysfunction, aphasia, and coordination 
and gait difficulties. 17 JCPyV virus is present in 38%-82% 
of the population 3,4 but is usually well-controlled by the 
immune system, resulting in asymptomatic latent infection. 
The kidney and bone marrow are the likely sites of latent 
infection,18 and there should be no JCPyV virus detectable 
in the CSF. PML primarily affects those with chronic and 
severely suppressed immune systems. 19 Three associations 
account for 90% of cases: (1) HIV; (2) immunosuppressing 
hematological malignancies, and (3) Multiple sclerosis pa-
tients treated with natalizumab, a monoclonal antibody to 
alpha-4 integrin that prevents immune cells accessing the 
central nervous system. 20 PML is rarely associated with 
organ transplantation, solid malignancies, sarcoidosis, and 
autoimmune disorders.20
Treatment for PML is via restoring immune function 
and/or attacking the virus. Restoring immune function can 
be achieved by reversal of the immunosuppression caused 
by a disease, for example antiretroviral drugs in HIV 21; re-
moval of immunosuppressive treatment for example stop-
ping Natalizumab 22 or speeding drug clearance through 
plasma exchange. 23 The second option is to attack the 
virus. Pavlovic et al 20 conducted a review of treatment op-
tions and divided them into 3 main groups: (1) antiviral 
agents (JCPyV cell entry inhibitors, retrograde transport 
inhibitors, inhibitors of DNA replication, antimalarials, 
poly-ADP-ribose polymerase-1 inhibitors and tyrosine 
kinase inhibitors), (2) immune response modulators (cy-
tokines and inflammation inhibitors), and (3) immunisa-
tion strategies (passive and active immunisation). Research 
supporting these options is limited to case studies and ret-
rospective studies with no strong consensus. Identification 
of successful treatment is difficult due to lack of an ade-
quate animal model, small patient numbers, and rapid dis-
ease progression.20
Prognosis in PML is poor. In HIV, 70% are alive at one year 
and 50% at 2 years. In those with MS treated with Natalizumab, 
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77% are alive at three years, and in those with active immunosup-
pressing hematological malignancies, 10% are alive at 2 months. 
20 A younger age at diagnosis, lower viral load of JCPyV, milder 
functional disability prior to PML diagnosis and more localized 
MRI brain involvement all appear to predict survival. 24
Developing PML after MM is rare with 11 case reports 
in the literature. 25-35 Presentations varied in these patients 
depending on the location of the lesion and included: hemi-
paresis and hemiplegia, 25,28,29,32,35 numbness and tingling 
of the legs,29 rapid cognitive decline, 25,27,33 homonymous 
hemianopia, 27 ataxia, 27 speech difficulties, 26,30-32,35 in-
continence, 26 apathy, 29 and memory impairment. 32-
34. Trying to identify if an individual aspect of the MM 
treatment was responsible for the development of PML 
is difficult from these isolated case studies. Thalidomide 
has indirectly been related in this case and two others 29,30 
and lenalidomide in four cases. 25-28 ASCT was used in all 
of the cases except two in which lenalidomide was used 
alone. 25,28 Lenalidomide is an immunomodulatory drug 
with antiangiogenetic, anti-inflammatory, and antiprolifer-
ative effects. Ying (2017) completed a systematic review 
and meta-analysis of the risk of serious infection in patients 
with MM receiving lenalidomide and found that the overall 
incidence of high-grade infection was 14.32%. Treatment 
for the PML varied in these case reports. Mirtazepine was 
used as a single agent in this case and 2 others; 26,27 in 
these cases, the patients died within 2-4 months. Yokokawa 
(2016) used mirtazepine in combination with mefloquine. 
In this case, the patient survived for more than one year 
from PML onset. Ripelino (2011) used mirtazapine in com-
bination with cidofovir and the patient survived for more 
than two years after onset of PML. It is not possible to rec-
ommend the most appropriate therapy from these reports; 
however, the use of combined treatments may improve out-
come. Treatment outcome may also be improved with early 
diagnosis.
There are difficult ethical questions about exposing pa-
tients to potentially harmful treatments when there is a 
lack of evidence of efficacy, even when prognosis is poor. 
Furthermore, any drug which is used must be able to cross 
the blood brain barrier and have acceptable side effects. 
There also needs to be consensus on how to measure out-
come. Some possible measures include: survival, neurolog-
ical examination, radiological lesion load and changes in 
JCPyV in the CSF. Until randomized control trials become 
available, the treatment of PML relies on case descriptions, 
retrospective studies, and informed discussions with patients.
PML is a rare complication of MM therapy and is asso-
ciated with high mortality and morbidity. Clinicians should 
consider this diagnosis when assessing patients with neuro-
logical symptoms and signs following treatment for MM. It 
is important that referrals are made promptly, and there is 
involvement of the multidisciplinary team with haematolo-
gists, neurologists, radiologists, virologists, and therapists.
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